BALAXINSEBALAXI PHARMACEUTICALS LIMITEDMediumNeutral
Announced Mon, 25 Aug · 15:41 IST

BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Proceedings of Annual General Meeting held on August 25, 2025

Board & Shareholder Meetings View source PDF

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Balaxi Pharmaceuticals held its 82nd Annual General Meeting on August 25, 2025, via video conferencing, chaired by Managing Director Ashish Maheshwari. Four ordinary resolutions were put to vote: adoption of audited standalone and consolidated financial statements, re-appointment of Mrs. Minoshi Maheshwari as a director (liable to retire by rotation), and appointment of secretarial auditors. Both the Statutory Auditor's Report and the Secretarial Audit Report were taken as read, with no qualifications except for a mention of a Rs. 1,35,000 fine paid to NSE for delay in appointing a women independent director. Remote e-voting was held from August 22-24, 2025, and the meeting concluded at 12:25 PM. The full proceedings are available on the company's website at www.balaxipharma.in.

Likely market impact

This was a routine procedural AGM with standard business items, indicating normal corporate functioning. The Rs. 1.35 lakh NSE fine for delayed appointment of a women independent director points to a minor past compliance lapse, but the financial impact is negligible and no material governance concerns were flagged in the audit reports.